Pacira BioSciences (PCRX) Treasury Shares (2010 - 2026)

Pacira BioSciences' Treasury Shares history runs 7 years deep, the most recent figure standing at $227.0 million for Q1 2026.

• On a quarterly basis, Treasury Shares rose 803.68% year-over-year to $227.0 million in Q1 2026; TTM through Mar 2026 was $227.0 million, a 803.68% increase from a year earlier, with the FY2025 full-year figure at $176.6 million, up 602.86% from the prior year.
• Treasury Shares grew to $227.0 million in Q1 2026 per PCRX's latest filing, from $176.6 million in the prior quarter.
• Across five years, Treasury Shares topped out at $9.0 million in Q1 2026 and bottomed at $837000.0 in Q2 2024.
• The 5-year median for Treasury Shares is $1.2 million (2022), against an average of $2.4 million.
• Across the five-year window, Treasury Shares jumped 200.61% in 2025 and surged 803.68% in 2026, its largest moves.
• Year by year, Treasury Shares stood at $25.1 million in 2024, then surged by 602.86% to $176.6 million in 2025, then gained by 28.57% to $227.0 million in 2026.
• Per Business Quant, the three latest PCRX Treasury Shares figures stand at $227.0 million (Q1 2026), $176.6 million (Q4 2025), and $125.5 million (Q3 2025).